Inventor · disambiguated record
Dean Eliott
Also filed as: ELIOTT DEAN
9 granted patents·7 pending applications·14 citations·filing 2009–2024
82Inventor score
Files withMASSACHUSETTS EYE & EAR INFIRMARY7ALDEYRA THERAPEUTICS INC5SCHEPENS EYE RES INST3AGRAWAL RAJAT1
Top patents by PatentIndex Score
16 records- 0192US11911385B1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·1 cites·20 claims
- 0291US10881548B2Methods of delivering an agent to the eyeMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2016·Granted Jan 5, 2021·8 cites·20 claims
- 0388US10098884B2Methotrexate for proliferative vitreoretinopathyMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2015·Granted Oct 16, 2018·3 cites·11 claims
- 0484US10828306B2Methotrexate for proliferative vitreoretinopathyMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2019·Granted Nov 10, 2020·1 cites·22 claims
- 0580US12005061B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·27 claims
- 0678US12005060B2Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2022·Granted Jun 11, 2024·0 cites·16 claims
- 0774US11739326B2RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transitionSCHEPENS EYE RES INST·Filed 2018·Granted Aug 29, 2023·1 cites·33 claims
- 0874US2024197740A1Methotrexate treatment methodsALDEYRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0971US2024390182A1Methods of delivering an agent to the eyeMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2024·Application pending·0 cites
- 1069US2024175022A1RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal TransitionSCHEPENS EYE RES INST·Filed 2023·Application pending·0 cites
- 1168US2021283135A1Methotrexate for proliferative vitreoretinopathyMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2020·Application pending·0 cites
- 1265US11963905B2Methods of delivering an agent to the eyeMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2021·Granted Apr 23, 2024·0 cites·18 claims
- 1365US2022370460A1Ophthalmic formulations of methotrexateALDEYRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1461US10272089B2Methotrexate for proliferative vitreoretinopathyMASSACHUSETTS EYE & EAR INFIRMARY·Filed 2017·Granted Apr 30, 2019·0 cites·22 claims
- 1561US2023355611A1Topotecan for proliferative vitreoretinopathySCHEPENS EYE RES INST·Filed 2023·Application pending·0 cites
- 1654US2010197826A1Wound Closing Compounds With AdditivesAGRAWAL RAJAT·Filed 2009·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →